Skip to main content
Year archive

IMMUPHARMA PLC — 2021 filings

All 55 regulatory filings released by IMMUPHARMA PLC (IMM) in 2021, sourced directly from the official regulator.

55 Filings
2021 Period
2021 filings (55)
Filing Released Lang
Holding(s) in Company
Major Shareholding Notification
2021-12-24 English
Subscriptions and Placing to raise £3.55 million
Share Issue/Capital Change
2021-12-20 English
Price Monitoring Extension
Share Issue/Capital Change
2021-12-15 English
Second Price Monitoring Extn
Regulatory Filings
2021-12-07 English
Price Monitoring Extension
Regulatory Filings
2021-12-07 English
COLLABORATION WITH IMPERIAL COLLEGE LONDON
Regulatory Filings
2021-11-29 English
Corporate Update
Investor Presentation
2021-11-18 English
Second Price Monitoring Extn
Regulatory Filings
2021-11-08 English
Price Monitoring Extension
Regulatory Filings
2021-11-08 English
Price Monitoring Extension
Regulatory Filings
2021-10-11 English
EURONEXT DELISTING
Delisting Announcement
2021-10-01 English
Euronext Delisting
Delisting Announcement
2021-10-01 English
PROF. SYLVIANE MULLER AWARDED ‘LEGION D’HONNEUR’
Regulatory Filings
2021-09-30 English
Interim Results for the 6months ended 30 June 2021
Earnings Release H1 2021
2021-09-29 English
IMM RNS Interims Results 29 September 2021 FINAL VERSION.pdf
Interim / Quarterly Report H1 2021
2021-09-29 English
Corporate Update
Management Reports
2021-09-29 English
Corporate Update
Regulatory Filings
2021-09-29 English
Second Price Monitoring Extn
Regulatory Filings
2021-09-22 English
Price Monitoring Extension
Regulatory Filings
2021-09-22 English
Director/PDMR Shareholding
Director's Dealing
2021-08-24 English
Director & PDMR Share Purchases
Director's Dealing
2021-08-24 English
Second Price Monitoring Extn
Interest Rate Update/Notice
2021-08-20 English
Price Monitoring Extension
Regulatory Filings
2021-08-20 English
Price Monitoring Extension
Regulatory Filings
2021-08-19 English
Notification of Major Holdings
Major Shareholding Notification
2021-08-17 English
FDA approves the Lupzuor™ PK study
Legal Proceedings Report
2021-08-12 English
IMM RNS Lupuzor Avion FDA PK Study FDA approval 12 August 2021
Regulatory Filings
2021-08-12 English
Second Price Monitoring Extn
Regulatory Filings
2021-08-10 English
Price Monitoring Extension
Regulatory Filings
2021-08-10 English
Board Changes
Board/Management Information
2021-07-30 English
Board Changes
Board/Management Information
2021-07-30 English
Board Appointment
Board/Management Information
2021-07-16 English
BOARD APPOINTMENT
Board/Management Information
2021-07-16 English
2021 RESULT OF ANNUAL GENERAL MEETING -REPLACEMENT
AGM Information
2021-06-28 English
2021 RESULT OF ANNUAL GENERAL MEETING
Declaration of Voting Results & Voting Rights Announcements
2021-06-28 English
Second Price Monitoring Extn
Regulatory Filings
2021-06-24 English
Price Monitoring Extension
Regulatory Filings
2021-06-24 English
Update: Lupzuor™ PK study
Legal Proceedings Report
2021-06-24 English
FDA to agree on the Lupzuor™ PK study via a written response to “Type C” meeting as Avion prepares for international Phase 3 trial
Regulatory Filings
2021-06-24 English
Notice of AGM and posting of Report & Accounts
Regulatory Filings
2021-06-02 English
IMM RNS Posting of RA and Notice of AGM 28 June 2021 FINAL.pdf
AGM Information
2021-06-02 English
Director Retirement
Board/Management Information
2021-05-24 English
DIRECTOR RETIREMENT
Board/Management Information
2021-05-24 English
Price Monitoring Extension
Regulatory Filings
2021-04-29 English
Final Results
Earnings Release FY 2020
2021-04-29 English
FINAL RESULTS ANNOUNCEMENT
Earnings Release FY 2020
2021-04-29 English
Immupharma 2020 Final accounts 28.04.21 - signed.pdf
Audit Report / Information FY 2020
2021-04-29 English
Second Price Monitoring Extn
Regulatory Filings
2021-04-16 English
Price Monitoring Extension
Regulatory Filings
2021-04-16 English
Second Price Monitoring Extn
Regulatory Filings
2021-02-25 English
Price Monitoring Extension
Regulatory Filings
2021-02-25 English
Update- scheduled Phase 3 trials in lupus patients
Legal Proceedings Report
2021-02-09 English
Lupuzor™ scheduled to commence international Phase 3 trial in Lupus patients in H2 2021
Legal Proceedings Report
2021-02-09 English
Appointment of Company Secretary
Regulatory Filings
2021-01-18 English
Holding(s) in Company
Major Shareholding Notification
2021-01-04 English